Patents Represented by Attorney, Agent or Law Firm Steve T. Zelson
  • Patent number: 5756539
    Abstract: A method of inhibiting one or more psychiatric disorders is disclosed comprising administering a compound of formula I ##STR1## wherein R.sup.1, R.sup.4 and R.sup.5 are individually hydrogen, hydroxy, halogen, trifluoromethyl, C.sub.1-6, alkyl, C.sub.1-6 alkoxy or (tertiary amino)C.sub.1-6 alkoxy; and R.sup.2 and R.sup.3 are individually hydrogen or C.sub.1-6 alkyl, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: February 20, 1997
    Date of Patent: May 26, 1998
    Assignee: Novo Nordis A/S
    Inventors: Birte Kloppenborg Skrumsager, Erik Bardrum Nielsen, Birgitte Hjort Guldhammer
  • Patent number: 5753683
    Abstract: The present invention relates to a novel method for treating a mammal suffering from or susceptible to schizophrenia and schizophreniform diseases.
    Type: Grant
    Filed: January 29, 1996
    Date of Patent: May 19, 1998
    Assignee: Novo Nordisk A/S
    Inventors: Franklin Porter Bymaster, Harlan E. Shannon
  • Patent number: 5753678
    Abstract: The present invention relates to novel N-substituted amino alcohols, amino acids and acid derivatives thereof in which a substituted alkyl chain forms part of the N-substituent or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation.
    Type: Grant
    Filed: September 18, 1996
    Date of Patent: May 19, 1998
    Assignee: Novo Nordisk A/S
    Inventors: Rolf Hohlweg, Tine Krogh J.o slashed.rgensen, Knud Erik Andersen, Uffe Bang Olsen, Peter Madsen, Zdenek Polivka, Otylie Konigova, Frantisek Miksik, Martina Kovandova, Alexandra Silhankova, Karel Sindelar
  • Patent number: 5753460
    Abstract: A variant of a parent .alpha.-amylase enzyme having an improved washing and/or dishwashing performance as compared to the parent enzyme, wherein one or more amino acid residues of the parent enzyme have been replaced by a different amino acid residue and/or wherein one or more amino acid residues of the parent .alpha.-amylase have been deleted and/or wherein one or more amino acid residues have been added to the parent .alpha.-amylase enzyme, provided that the variant is different from one in which the methionine residue in position 197 of a parent B. licheniformis .alpha.-amylase has been replaced by alanine or threonine, as the only modification being made. The variant may be used for washing and dishwashing.
    Type: Grant
    Filed: October 10, 1996
    Date of Patent: May 19, 1998
    Assignee: Novo Nordisk A/S
    Inventors: Henrik Bisgard-Frantzen, Torben Vedel Borchert, Allan Svendsen, Marianne Thellersen, Pia Van der Zee
  • Patent number: 5753643
    Abstract: The present invention relates to novel N-substituted azaheterocyclic carboxylic acids and esters thereof in which a substituted alkyl chain forms part of the N-substituent or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation.
    Type: Grant
    Filed: May 22, 1997
    Date of Patent: May 19, 1998
    Assignee: Novo Nordisk A/S
    Inventors: Henrik Sune Andersen, Knud Erik Andersen, Rolf Hohlweg, Peter Madsen, Tine Krogh J.o slashed.rgensen, Uffe Bang Olsen
  • Patent number: 5752980
    Abstract: The present invention relates to a process for providing a bleached look in the color density of the surface of dyed fabric, especially cellulosic fabric such as denim, comprising use of a phenol oxidizing enzyme such as a peroxidase or a laccase, a hydrogen peroxide source and an enhancing agent represented by formula (I).
    Type: Grant
    Filed: February 4, 1997
    Date of Patent: May 19, 1998
    Assignee: Novo Nordisk A/S
    Inventors: Anders Hjelholt Pedersen, Jesper Vallentin Kierulff
  • Patent number: 5753487
    Abstract: This invention relates to stabilization of phenylalanine ammonia lyase against proteolytic degradation by chemical modification with crosslinking agents, or by genetic modification, a phenylalanine ammonia lyase variant, a method of preparing the variant and a pharmaceutical composition containing phenylalanine ammonia lyase.
    Type: Grant
    Filed: December 12, 1995
    Date of Patent: May 19, 1998
    Assignee: Novo Nordisk A/S
    Inventors: Peter Eigtved, Ib Groth Clausen
  • Patent number: 5750541
    Abstract: The present invention relates to a novel method for treating a mammal suffering from or susceptible to schizophrenia and schizophreniform diseases by administering thiadiazole or oxadiazole compounds.
    Type: Grant
    Filed: August 2, 1996
    Date of Patent: May 12, 1998
    Assignee: Novo Nordisk A/S
    Inventors: Franklin Porter Bymaster, Harlan E. Shannon
  • Patent number: 5750140
    Abstract: A transdermal delivery system containing tiagabine or its pharmaceutically acceptable salts or esters is disclosed. The delivery system is useful in the treatment of epilepsy.
    Type: Grant
    Filed: May 12, 1995
    Date of Patent: May 12, 1998
    Assignee: Novo Nordisk A/S
    Inventors: Helle Weibel, Peter Bonne Eriksen
  • Patent number: 5750497
    Abstract: The present invention relates to human insulin derivatives having a protracted profile of action in which the A21 and B3 amino acid residues are, independently, any amino acid residue which can be coded for by the genetic code except Lys, Arg and Cys; Phe.sup.B1 may be deleted; the B30 amino acid residue is (a) a non-codable, lipophilic amino acid having from 10 to 24 carbon atoms in which case an acyl group of a carboxylic acid with up to 5 carbon atoms is bound to the E-amino group of Lys.sup.B29 ; (b) any amino acid residue which can be coded by the genetic code except Lys, Arg and Cys, in which case a lipophilic substituent is bound to the E-amino group of Lys.sup.B29 ; or (c) deleted, in which case a lipophilic substituent is bound to the E-amino group of LyS.sup.B29 ; and any Zn.sup.2+ complexes thereof; provided that when the B30 amino acid residue is Thr or Ala, the A21 and B3 amino acid residues are both Asn and Phe.sup.B1 is present, then the insulin derivative is a Zn.sup.2 + complex.
    Type: Grant
    Filed: March 8, 1995
    Date of Patent: May 12, 1998
    Assignee: Novo Nordisk A/S
    Inventors: Svend Havelund, John Halstr.o slashed.m, Ib Jonassen, Asser Sloth Andersen, Jan Markussen
  • Patent number: 5750538
    Abstract: The present invention relates to a novel method for treating a mammal suffering from hypercholesterolemia and related disorders.
    Type: Grant
    Filed: January 3, 1997
    Date of Patent: May 12, 1998
    Assignee: Novo Nordisk A/S
    Inventors: Per Sauerberg, Kristian Tage Hansen
  • Patent number: 5750518
    Abstract: The present invention relates to novel N-substituted azaheterocyclic carboxylic acids and esters thereof in which a substituted alkyl chain forms part of the N-substituent or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation.
    Type: Grant
    Filed: May 27, 1997
    Date of Patent: May 12, 1998
    Assignee: Novo Nordisk A/S
    Inventors: Tine Krogh J.o slashed.rgensen, Knud Erik Andersen, Henrik Sune Andersen, Rolf Hohlweg, Peter Madsen, Uffe Bang Olsen
  • Patent number: 5747481
    Abstract: The present invention relates to novel N-substituted azaheterocyclic carboxylic acids and esters thereof in which a substituted alkyl chain forms part of the N-substituent or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation.
    Type: Grant
    Filed: May 27, 1997
    Date of Patent: May 5, 1998
    Assignee: Novo Nordisk A/J
    Inventors: Tine Krough J.o slashed.rgensen, Knud Erik Andersen, Henrik Sune Andersen, Rolf Hohlweg, Peter Madsen, Uffe Bang Olsen
  • Patent number: 5744489
    Abstract: The present invention relates to a method for treating a mammal suffering from gastrointestinal motility disorders comprising administering certain thiadiazole and oxadiazole compounds that are herein disclosed.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: April 28, 1998
    Inventor: Beverley Greenwood
  • Patent number: 5744323
    Abstract: The present invention relates to methods for producing heterologous heme proteins extracellularly comprising transforming a filamentous fungus with a vector comprising a DNA sequence encoding the heterologous heme protein and a DNA sequence encoding a preregion permitting secretion of the expressed heme protein, and culturing the transformed filamentous fungus in a suitable culture medium to produce the heme protein.
    Type: Grant
    Filed: September 30, 1994
    Date of Patent: April 28, 1998
    Assignee: Novo Nordisk A/5
    Inventors: Henrik Dalb.o slashed.ge, Ejner Bech Jensen, Karen Gjesing Welinder
  • Patent number: 5741216
    Abstract: The present invention is a pressure monitor for measuring the pressure in a liquid in catheter, comprising a light emitting device, a photosensitive device receiving the light from the light emitting device and transforming the light received into electric signals. The invention also includes a measuring zone. The light transmitted through the measuring zone varies in accordance with the pressure in the catheter.
    Type: Grant
    Filed: November 4, 1994
    Date of Patent: April 21, 1998
    Assignee: Novo Nordisk A/S
    Inventors: Allan Hemmingsen, Bo Steffensen
  • Patent number: 5741688
    Abstract: A glucose oxidase obtained from a Cladosporium oxysporum strain, designated as CBS 163.94, characterized by a pH-optimum in he range pH 6-7, having more than 75% of maximum activity at pH 8, determined at 30.degree. C. with D-glucose as substrate.
    Type: Grant
    Filed: May 25, 1995
    Date of Patent: April 21, 1998
    Assignee: Novo Nordisk A/S
    Inventors: Karen M. Oxenb.o slashed.ll, Joan Qi Si, Jesper Aagaard
  • Patent number: 5741785
    Abstract: Imidazo?1,2-a!quinoxalinone derivatives of the general formula ##STR1## wherein R.sup.1, R.sup.2, R.sup.3 are the same or independently are H, alkyl, alkoxy, halogen, NO.sub.2, NH.sub.2, CF.sub.3, CN, SO.sub.2 CH.sub.3, SO.sub.2 CF.sub.3, SO.sub.2 NR'R" or a 5- or 6-membered N-containing heterocyclic ring, optionally substituted, and R', R" are independently H or alkyl; and R.sup.4 is H or CH.sub.2 -R.sup.6 ; and R.sup.6 is H, halogen, POR'"R"", NR.sup.7 R.sup.8 or a 5- or 6-membered N-containing heterocyclic ring optionally substituted, and R'", R"" are independently hydroxy or alkoxy; and ##STR2## R.sup.7, R.sup.8 are the same or independently are H, or alkyl optionally substituted; and n is 1, 2 or 3;R.sup.5 is ##STR3## and R.sup.9 is OH, alkoxy, H or NR.sup.10 R.sup.11 ; and R.sup.10, R.sup.11 are the same or independently are H, NH.sub.2 or OH; and X is O or S; and Y is O, S or NH.sub.
    Type: Grant
    Filed: February 8, 1995
    Date of Patent: April 21, 1998
    Assignee: Novo Nordisk A/S
    Inventor: Lone Jeppesen
  • Patent number: 5741791
    Abstract: The present invention relates to the use of compounds of the general formula ##STR1## for reducing blood glucose and/or inhibit the secretion, circulation or effect of insulin antagonizing peptides like CGRP or amylin. Hence the compound can be used in the treatment of insulin resistance related to NIDDM (non-insulin-dependent diabetes mellitus) or aging.
    Type: Grant
    Filed: December 13, 1996
    Date of Patent: April 21, 1998
    Assignee: Novo Nordisk A/S
    Inventor: Uffe Bang Olsen
  • Patent number: 5741693
    Abstract: The present invention relates to proteases obtained from a strain of Bacillus sp. AC13, and having (a) an apparent molecular weight of approximately 30 kD as determined by SDS-PAGE; (b) an isoelectric point of approximately 9.3 as determined by isoelectric focusing on LKB Ampholine PAG plates; (c) a pH optimum above 10 determined at 25.degree. C. with casein as substrate; (d) a temperature optimum in the range of 45.degree.-55.degree. C. determined at pH 9.5 with casein as substrate; and (e) immunochemical properties identical or partially identical to those of a protease derived from Bacillus sp. AC13, NCIMB No. 40482.
    Type: Grant
    Filed: November 30, 1994
    Date of Patent: April 21, 1998
    Assignee: Novo Nordisk A/S
    Inventors: Helle Outtrup, Claus Dambmann, Arne Agerlin Olsen, Henrik Bisg.ang.rd-Frantzen, Martin Schulein